CJC-1295 vs Ipamorelin

Side-by-side comparison of CJC-1295, Ipamorelin — mechanism, dosing, half-life, side effects, and research status.

← Pick different peptides
Attribute CJC-1295 CJC-1295 (Modified GRF 1-29) Growth Hormone Ipamorelin Ipamorelin (Selective GHRP) Growth Hormone
Basics
Molecular type GHRH AnalogueGrowth Hormone Releasing Peptide (GHRP)
Amino acids 295
Molecular weight 3,368.9 Da711.9 Da
Half-life 30 min (without DAC) / 7–8 days (with DAC)~2 hours
Route(s) Subcutaneous, IntramuscularSubcutaneous, Intramuscular
Mechanism & Research
Primary mechanism CJC-1295 binds GHRH receptors on pituitary somatotroph cells, stimulating GH synthesis and increasing GH pulse amplitude. Unlike native GHRH (half-life <10 minutes), the modified amino acid substitutions in CJC-1295 resi… Ipamorelin activates growth hormone secretagogue receptors (GHSR-1a) in the pituitary, triggering pulsatile GH release. Unlike first-generation GHRPs (GHRP-6, GHRP-2), ipamorelin's selectivity for GHSR-1a is high enough …
Research status Research Compound Research Compound
Evidence summary Phase 1/2 trials with CJC-1295 with DAC confirmed dose-dependent IGF-1 elevation lasting up to 14 days after single injection. CJC-1295 without DAC's pulsatile profile is primarily studied in combination with GHRPs. Ipamorelin was among the first highly selective GHRPs to enter research. Phase 1 trials confirmed its clean hormonal profile. It remains a reference GHRP in comparative studies and is widely used as the GHRP component in…
Protocol & Dosing
Typical dose 100–200 mcg (without DAC); 2mg every 2 weeks (with DAC)100–300 mcg per injection
Frequency 2–3x daily (without DAC); biweekly (with DAC)2–3x daily (or 1x at bedtime)
Duration 8–16 weeks8–12 weeks on, 4 weeks off
Timing Without DAC: fasted, 2x daily ideally morning + bedtime. With DAC: any time, biweekly.Fasted state or 2+ hours post-meal for maximum GH response; bedtime dosing utilises natural nocturnal GH pulse
Safety
Common side effects
  • Water retention
  • Mild headache
  • Flushing (post-injection)
  • Tingling
  • Water retention (mild)
  • Tingling/numbness (extremities)
  • Headache (transient)
  • Injection site redness
Contraindications
  • Active malignancy
  • Uncontrolled hypothyroidism
  • Pregnancy
  • Active malignancy
  • Uncontrolled diabetes
  • Pregnancy
Anti-doping Prohibited (WADA S2) Prohibited (WADA S2)
Deeper reading
Related peptides Ipamorelin, Sermorelin, GHRP-2, Tesamorelin CJC-1295, GHRP-2, Sermorelin, Tesamorelin
Full profile Read full CJC-1295 profile → Read full Ipamorelin profile →

Comparison data is compiled from each peptide’s individual profile. All values are drawn from peer-reviewed research and regulatory sources. For educational use only — not medical advice. Verify any protocol with a qualified healthcare provider.